Skip to main content

Table 1 Characteristics of 18 sHLH patients

From: The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis

No.

Age/ Sex

Underlying disease

Therapy

Outcome

Survival (month)

Organs

SUVmax

1

35/M

Lymphoma (NK / T)

IVIG/HLH-2004 regimen(1 cycle) → High-dose methylprednisolone pulse therapy

Died of intracranial hemorrhage

1.7

6

12.3

2

35/F

Lymphoma (NK / T)

The Hyper-CVAD regimen (1 cycle)

Died of intracranial hemorrhage

1.2

6

15.7

3

18/M

Lymphoma (NK / T)

The CHOP regimen(1 cycle)

Died of acute hemorrhage of gastrointestinal tract

0.3

7

14.6

4

56/M

Lymphoma

Hydrocortisone 100mg×5d

Died of intracranial hemorrhage

1.7

5

4.3

5

32/M

Lymphoma

Dex 10mg/d×3d

Died of liver failure

0.3

10

13.3

6

37/F

Sjögren's syndrome

The COP regimen(3 cycle)

CR

>12

5

0.7

7

15/F

UCTD

The COP regimen (4 cycle)

CR

>45

3

4.6

8

21/F

EBV infection

HLH-2004 regimen (1 cycle)

Died of acute hemorrhage of gastrointestinal tract

1.7

7

6.6

9

17/M

EBV infection

Methylprednisolone 40 mg/d×24d

CR

>22

7

8.3

10

46/M

EBV infection

Dex 15mg/d×4d

Died of septic shock

0.4

6

10

11

73/M

EBV infection

The COP regimen (7 cycle)

Died of multi-organ failure

6

7

5.2

12

26/F

CMV infection

IVIG/HLH-2004 regimen (1 cycle) →The CHOP regimen(2 cycle)

CR

>24

6

9

13

24/F

CMV infection

The COP regimen (7 cycle)

Died of respiratory failure

2.2

5

4.2

14

69/F

MRSH infection

The COP regimen (2 cycle)

Died of respiratory failure

2.0

6

5.2

15

62/F

Fungal Infection

The COP regimen (7 cycle)

stable

>8

4

5.8

16

44/F

Malignant tumour?

Methylprednisolone 40 mg/d×5d

Died of multi-organ failure

0.4

8

7.7

17

56/M

Lymphoma?

The CHOP regimen (2 cycle) →Splenectomy→The Hyper-CVAD regimen (1cycle)

stable

>13

6

5.7

18

18/M

indefinite

HLH-2004 regimen (1 cycle)

Died of intracranial hemorrhage

0.2

3

4.2

  1. HLH-2004, dexamethasone, etopside and Ciclosporin A; CHOP, cyclophosphamide, adviamycin, vincristine and prednisolone; COP, cyclophosphamide, vincristine and prednisone; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine; DEX, dexamethasone; CR, complete response; UCTD, undifferentiated connective tissue disease; EBV, Epstein-Barr virus; CMV, cytomegalovirus; MRSH, methicillin-resistant Staphylococcus hominis.